GGrantIndex
← Leaderboards

Jeffrey L Bennett

University Of Colorado Denver

$6,992,785
Attributed
$9,650,470
Total exposure
7
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,650,470 · 7

By mechanism

R01$7,073,742 · 3
U24$1,273,996 · 1
K08$458,586 · 1
R03$458,131 · 1
R21$386,015 · 1

Top collaborators

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Complement

Research focus

ComplementResponseCellsNeurologicMediatingIn VivoInflammatoryRecombinant AntibodyAntibodiesImmunoglobulin GDemyelinationsAutoantibodiesLesionBrainCentral Nervous System InjuryInjuryDisabilityCentral Nervous System Demyelinating DisorderTissuesMyelinOligodendrogliaCerebrospinal FluidNeuraxisIn Vivo Model

Grant awards (28)

University of Colorado Rocky Mountain NeuroNEXT (UNCOMON) Clinical Research Consortium.$428,955
U24 · FY2025 · NS · contact PI
Contribution of antibodies targeting PLP1-anchored membrane domains to multiple sclerosis pathogenesis$406,815
R01 · FY2025 · NS · contact PI
Microglial impact on remyelination$472,792
R01 · FY2024 · NS
University of Colorado Rocky Mountain NeuroNEXT (UNCOMON) Clinical Research Consortium.$416,086
U24 · FY2024 · NS · contact PI
Contribution of antibodies targeting PLP1-anchored membrane domains to multiple sclerosis pathogenesis$405,282
R01 · FY2024 · NS · contact PI
Microglial impact on remyelination$487,413
R01 · FY2023 · NS
University of Colorado Rocky Mountain NeuroNEXT (UNCOMON) Clinical Research Consortium.$428,955
U24 · FY2023 · NS · contact PI
Microglial impact on remyelination$487,413
R01 · FY2022 · NS
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica$377,088
R01 · FY2022 · EY · contact PI
In vivo modeling of autoantibody-induced optic neuritis$171,564
R21 · FY2022 · EY
Microglial impact on remyelination$487,413
R01 · FY2021 · NS
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica$377,087
R01 · FY2021 · EY · contact PI
In vivo modeling of autoantibody-induced optic neuritis$214,451
R21 · FY2021 · EY
Microglial impact on remyelination$483,565
R01 · FY2020 · NS
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica$388,750
R01 · FY2020 · EY · contact PI
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica$388,750
R01 · FY2019 · EY · contact PI
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica$388,750
R01 · FY2018 · EY · contact PI
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica$388,750
R01 · FY2017 · EY · contact PI
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica$388,750
R01 · FY2016 · EY · contact PI
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica$380,362
R01 · FY2015 · EY · contact PI
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica$379,137
R01 · FY2014 · EY · contact PI
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica$385,625
R01 · FY2013 · EY · contact PI
Antigen Identification in Occult Chorioretinopathies$150,381
R03 · FY2006 · EY · contact PI
Antigen Identification in Occult Chorioretinopathies$154,000
R03 · FY2005 · EY
Antigen Identification in Occult Chorioretinopathies$153,750
R03 · FY2004 · EY
GROWTH FACTORS IN MAMMALIAN EYE DEVELOPMENT$152,862
K08 · FY2002 · EY
GROWTH FACTORS IN MAMMALIAN EYE DEVELOPMENT$152,862
K08 · FY2001 · EY
GROWTH FACTORS IN MAMMALIAN EYE DEVELOPMENT$152,862
K08 · FY2000 · EY